Julie was given two years to live after being diagnosed with secondary breast cancer. Seven years later she is still here, telling her story.
Sarah was diagnosed with breast cancer in May 2010. This insightful patient story details how she has coped with her diagnosis over the last few years.
The Haven is a breast cancer charity that offers advice and support to cancer patients if their cancer returns. Learn more.
Sometimes cancer patients find out that their cancer has returned. The Haven is a breast cancer charity that offers advice and support to cancer patients in this position.
For many men, coping with a “woman’s disease” can be tough. Watch to learn about the difficulties of male breast cancer.
Men diagnosed with breast cancer often know little about medical procedures to treat it. Learn here about going to the doctor with breast cancer
Learn about treatment for male breast cancer, and hear from a cancer patient in our video interview.
Breast cancer can affect men but is rare. Learn what the risk factors for men are for developing breast cancer.
Men with breast cancer often complain that there is not enough information available that targets male cancer patients. Learn more.
Learn more about breast cancer in our short video interview with a breast care nurse specialist.
When Melanie was diagnosed with advanced breast cancer, she was told that her chances of surviving were slim. Now after surgery and several years of treatment she is enjoying her life to the fullest.
Chemotherapy uses a range of drugs to treat breast cancer. In this video we examine monotherapy and combination therapy and answer the question what is chemotherapy?
Metastatic cancer describes when cancer cells have migrated from the primary cancer site to another part of the body. Learn more about metastasis from our video.
Adjusting to a diagnosis of metastatic breast cancer can be a difficult process. Watch our interview with a healthcare professional to find out more.
Clinical trials exist to test the efficacy of drugs and other treatments. Watch our video on clinical trials and breast cancer.
Clinical trials exist to test the efficacy of drugs and other treatments. Watch our video on clinical trials terminology.
Hormone sensitive breast cancer is fuelled by naturally produced female hormones. Turning the fuel supply off can make a difference.
Breast Cancer is the most common cancer affecting women in the UK. Watch our video series to find out about breast cancer help and support.
Susan has been undergoing treatments for metastatic breast cancer for more than 6 years.
What can a clinical trial do for you? Watch this video to find out
A video explaining the types of and treatment for advanced breast cancer available to patients and the considerations needed when choosing therapy.
The body produces two hormones called oestrogen and progesterone. Breast cancer tumours are often sensitive to these hormones. This means that without the hormones the cancer cells stop reproducing or die.
Patients with breast cancer require a biopsy test to determine the oestrogen and progesterone receptor status of the tumour. These tests tell if the tumour is fuelled by either of those hormones. If the test comes back positive we can call the cancer hormone-sensitive. Cancer that is hormone-sensitive usually grows slightly slower than non-sensitive cancer and will respond better to hormone-suppression treatment.
If your breast cancer tumour is tested and is found to be Oestrogen Receptor positive (ER+) this means that the oestrogen produced in your body is helping the tumour grow. Hormone suppression treatment that stops your body producing oestrogen can help fight the cancer. If the tumour score is Oestrogen Receptor negative (ER-), then the tumour is not fuelled by oestrogen production and hormone suppression treatment will not be effective.
If your breast cancer tumour scores Progesterone Receptor positive (PR+) this means that the progesterone produced in your body is helping the tumour grow and the cancer should respond to hormone-suppression treatments. If it scores Progesterone Receptor negative (PR-) then the tumour is not fuelled by progesterone production and these treatments will be less effective.
If your hormone receptor test results come back negative, it is advisable to ask your doctor to provide a numerical score. Hormone receptor scores range from 0 to 3 indicating the number of hormone receptors present in the biopsy sample. The higher the number of receptors, the more likely it is that the cancer will respond to hormone suppression treatment. However, tumours with low receptor scores may still respond to hormone suppression treatments so it’s a good idea to know your score.
Hormone receptor scores can be broken down as follows:
• 0 no receptors found
• 1+ is a small number of receptors
• 2+ is a medium number of receptors
• 3+ is a large number of receptors
Sometimes your test results will be provided as a percentage. When 100 cells are tested, a certain number have hormone receptors. This number is your receptor score. A score of 0% means that no cells have receptors – the cancer will not respond to hormone suppression treatments. A score of 100% means that all the cells have receptors and the cancer should respond well to hormone suppression treatment.
HER2 is a gene that transmits signals to your cells, telling them to grow, divide, and make repairs. Some types of breast cancer occur when a breast cell has more than 2 copies of that gene, and those copies start over-producing the HER2 protein. The affected cells grow and divide much too quickly, causing a tumour to develop.
Breast cancer tested for HER2 status that scores positive means that the cancer is caused by your HER2 genes over-producing the HER2 protein. If the HER2 score is negative then the HER2 gene did not cause the breast cancer.
If your breast cancer scores positive for either oestrogen or progesterone receptor status then you’ll receive treatment to block your body’s production of that hormone. This will use one of a number of hormone suppression drugs.
Herceptin is the drug used to treat HER2 positive breast cancer. Herceptin targets the HER2 protein production. This helps to stop the growth of the HER2 positive cancer cells.
Some types of breast cancer score negative for oestrogen, progesterone and HER2 receptor status. These types of cancer are referred to as “triple negative cancers”. Triple negative cancers do not respond to hormone suppression treatment or Herceptin. In these cases patients will receive chemotherapy, which is more effective in the treatment of triple negative breast cancer.
10639 Published April 2012
Review Scheduled April 2013comments powered by Disqus